MARKET

HRMY

HRMY

Harmony Biosciences Holdings, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

39.60
-1.84
-4.44%
After Hours: 39.60 0 0.00% 16:00 10/28 EDT
OPEN
40.39
PREV CLOSE
41.44
HIGH
41.21
LOW
38.44
VOLUME
248.34K
TURNOVER
--
52 WEEK HIGH
47.37
52 WEEK LOW
28.97
MARKET CAP
2.49B
P/E (TTM)
-17.2926
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Harmony Biosciences Announces Date Of Third Quarter 2020 Financial Results
Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that it will issue a press release on the Company's third quarter financial results on Thursday, November 12, 2020 at 8:00 a.m. ET. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.
PR Newswire · 12h ago
Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX® (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy
PR Newswire · 10/14 13:05
FDA ok's expanded use of Wakix
The FDA has approved Harmony Biosciences's (HRMY) WAKIX (pitolisant) for the treatment of cataplexy in adult patients with narcolepsy. WAKIX received FDA approval for the treatment of excessive daytime sleepiness
Seekingalpha · 10/14 12:54
The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx's Positive Preannouncement, Aziyo Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs Oct. 7)
Benzinga · 10/08 11:52
Mid-Afternoon Market Update: Dow Tumbles 400 Points; JinkoSolar Shares Jump
Toward the end of trading Wednesday, the Dow traded down 1.47% to 26887.20 while the NASDAQ fell 2.44% to 10,695.38. The S&P also fell, dropping 1.77% to 3,257.05.
Benzinga · 09/23 18:57
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)
Benzinga · 09/23 12:05
Harmony Biosciences Announces Recipients Of 2020 Patients At The Heart Grant On Second Annual World Narcolepsy Day
Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced recipients of the second-annual Patients
PR Newswire · 09/22 13:05
The Daily Biotech Pulse: Legal Relief For Evolus, Fulgent to Join S&P SmallCap 600, AIM ImmunoTech's Positive Cancer Drug Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 21)
Benzinga · 09/22 11:59
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HRMY. Analyze the recent business situations of Harmony Biosciences Holdings, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HRMY stock price target is 51.67 with a high estimate of 61.00 and a low estimate of 43.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 62.98M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HRMY
Harmony Biosciences Holdings, Inc. is a holding company. The Company through its subsidiary, Harmony Biosciences, LLC., operates as a pharmaceutical company, which is focused on therapies for patients suffering from central nervous system disorders living with medical needs. It provides treatment options for people living with rare and orphan diseases, with an emphasis on central nervous system disorders, patients living with narcolepsy. It enables to know narcolepsy and provides information and resources to individuals who live with, and healthcare professionals who treat patients with, this disorder. Narcolepsy is a chronic, debilitating neurologic disorder of sleep-wake state instability. The Company’s product, WAKIX (pitolisant), is a molecule with an action, designed to histamine signaling in the brain by binding to H3 receptors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Harmony Biosciences Holdings Inc stock information, including NASDAQ:HRMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRMY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HRMY stock methods without spending real money on the virtual paper trading platform.